Pancreatic Adenocarcinoma Metastatic Clinical Trials

9 recruiting

Pancreatic Adenocarcinoma Metastatic Trials at a Glance

9 actively recruiting trials for pancreatic adenocarcinoma metastatic are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Boston, New York, and Madrid. Lead sponsors running pancreatic adenocarcinoma metastatic studies include Clinica Universidad de Navarra, Universidad de Navarra, Evopoint Biosciences Inc., and Abramson Cancer Center at Penn Medicine.

Browse pancreatic adenocarcinoma metastatic trials by phase

Treatments under study

About Pancreatic Adenocarcinoma Metastatic Clinical Trials

Looking for clinical trials for Pancreatic Adenocarcinoma Metastatic? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pancreatic Adenocarcinoma Metastatic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pancreatic Adenocarcinoma Metastatic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 3

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Immuneering Corporation510 enrolled3 locationsNCT07562152
Recruiting
Phase 3

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.900 enrolled2 locationsNCT07491445
Recruiting
Phase 1

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Breast Cancer MetastaticPancreatic CancerHER2-negative Breast Cancer+9 more
General Oncology, Inc.24 enrolled2 locationsNCT04150042
Recruiting
Phase 1

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma Metastatic
Oncomatryx Biopharma S.L.69 enrolled7 locationsNCT07377045
Recruiting
Phase 1Phase 2

TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)

Pancreatic Adenocarcinoma MetastaticPancreatic Ductal Adenocarcinoma
Clinica Universidad de Navarra, Universidad de Navarra30 enrolled5 locationsNCT07284277
Recruiting
Phase 2

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

Pancreatic Adenocarcinoma Metastatic
Abramson Cancer Center at Penn Medicine68 enrolled2 locationsNCT06747845
Recruiting
Phase 1Phase 2

XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.

Biliary Tract CancerOvarian CancerGastric Carcinoma+4 more
Evopoint Biosciences Inc.240 enrolled1 locationNCT06792435
Recruiting
Phase 2

PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC

Pancreatic Adenocarcinoma Metastatic
Sun Yat-sen University20 enrolled1 locationNCT06396637
Recruiting
Phase 2

Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer

Pancreatic Adenocarcinoma Metastatic
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School177 enrolled1 locationNCT06051851